Floatz logo

TACROLIMUS

Transplantation, Bone Marrow

Stanford UniversitySmall moleculePhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Transplantation, Bone Marrow cohort.

Asset / SponsorPhaseRating
Fludarabine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2BB
Busulphan
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2BB
Cyclophosphamide
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2B
Romidepsin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2B
Monomethyl Fumarate
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2B
Clofarabine
M.D. Anderson Cancer Center
Phase 1CC
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 1CC
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
M.D. Anderson Cancer Center
Phase 1CC

Same molecule, other indications

TACROLIMUS is also rated in:

disease related to transplantationDormant
BBB
Indicative ·
79 / 100
View asset →
disease related to solid organ transplantationDormant
BBB
Indicative ·
76 / 100
View asset →
beta-thalassemia majorDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →